Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.

Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2018 Sep 28. doi: 10.1007/s00345-018-2506-1. [Epub ahead of print]

PMID:
30267197
2.

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.

Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Sep 15. pii: S1078-1439(18)30305-3. doi: 10.1016/j.urolonc.2018.08.009. [Epub ahead of print]

PMID:
30228094
3.

Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center.

Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE.

Urol Oncol. 2018 Sep;36(9):401.e19-401.e25. doi: 10.1016/j.urolonc.2018.06.006. Epub 2018 Jul 29.

PMID:
30064933
4.

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2018 May 11. doi: 10.1007/s00345-018-2327-2. [Epub ahead of print]

PMID:
29752514
5.

Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.

Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K.

Urol Pract. 2018 Mar;5(2):132-138. doi: 10.1016/j.urpr.2017.02.012. Epub 2017 Mar 2.

6.

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.

Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.

Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. Review.

7.

Trends in urinary diversion after radical cystectomy for urothelial carcinoma.

Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K.

World J Urol. 2018 Mar;36(3):409-416. doi: 10.1007/s00345-017-2169-3. Epub 2018 Jan 3.

PMID:
29299664
8.

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.

Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A.

Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Review.

PMID:
29199023
9.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
10.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
11.

Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.

Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K.

Urol Oncol. 2018 Jan;36(1):9.e1-9.e9. doi: 10.1016/j.urolonc.2017.09.001. Epub 2017 Oct 20.

PMID:
29066013
12.

Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.

Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB.

Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30215-X. doi: 10.1016/j.clgc.2017.07.018. [Epub ahead of print]

PMID:
28826932
13.

Trends in Aging-Related Services During Nephrectomy: Implications for Surgery in an Aging Population.

Tan HJ, Litwin MS, Chamie K, Saliba D, Hu JC.

J Am Geriatr Soc. 2017 Oct;65(10):2290-2296. doi: 10.1111/jgs.15046. Epub 2017 Aug 11.

14.

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD.

Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26.

PMID:
28755959
15.

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K.

J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4. Review.

PMID:
28479237
16.

Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO Jr, Williams MA, Giordano SH, Kim SP, Kamat AM.

Cancer Causes Control. 2017 Jul;28(7):755-766. doi: 10.1007/s10552-017-0902-2. Epub 2017 May 5.

17.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.

Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26.

PMID:
28341495
18.

Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.

Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF.

Cancer. 2017 May 1;123(9):1617-1624. doi: 10.1002/cncr.30506. Epub 2017 Jan 18.

19.

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.

Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.

Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3.

PMID:
28065395
20.

Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.

Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20.

Supplemental Content

Loading ...
Support Center